Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

GENEVA, SWITZERLAND / ACCESSWIRE / September 30, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that its wholly owned subsidiary, APR Applied Pharma Research SA ("APR"), reported data published in the peer reviewed Journal of Wound Care, indicating that the company's Nexodyn(R) acid-oxidizing solution (AOS), developed with APR's proprietary Tehclo(R) technology, was found to be a highly effective treatment to support wound healing in infected or non-infected hard-to-heal leg ulcers. The data also confirmed the safety and tolerability of Nexodyn(R).

https://www.biospace.com/article/releases/relief-s-subsidiary-apr-applied-pharma-research-reports-data-published-in-journal-of-wound-care-indicating-nexodyn-r-aos-highly-effective-treatment-to-support-healing-of-hard-to-heal-leg-ulcers/

“Venous Leg Ulcer Treatment (VLU) Market Size, Share and Global Trend by Product (Compression Therapy, Advanced Wound Dressings, Others), By End User (Hospitals, Specialty Clinics, Homecare Settings, Others), and Regional Forecast, till 2026,” the market was worth USD 2.95 billion in 2018 and will exhibit a CAGR of 6.4% during the forecast period, 2019-2026.

https://www.globenewswire.com/news-release/2020/03/03/1994141/0/en/Venous-Leg-Ulcer-Treatment-Market-to-Rise-at-6-4-CAGR-till-2026-Increasing-Investments-in-Product-R-D-to-Aid-Growth-says-Fortune-Business-Insights.html